loader image
Funded Investigators:
Prof. Alan Dobson, University College Cork, Prof. Fergal O’Gara, University College Cork, Dr Marina Rubini, University College Dublin, Prof. Edmond Magner, University of Limerick, Prof. Stephen Connon, Trinity College Dublin, Dr Eoghan McGarrigle, University College Dublin, Dr Gerard McGlacken, University College Cork, Dr Paul Evans, University College Dublin, Prof. Declan Gilheany, University College Dublin, Dr Andrew Phillips, University College Dublin, Prof. Paul Murphy, NUI Galway, Dr Peter Byrne, University College Cork, Dr Stuart Collins, University College Cork, Prof. Eoin Scanlan, Trinity College Dublin, Prof. Joanna McGouran, Trinity College Dublin.
Theme Leaders:
Prof. Anita Maguire
University College Cork
Molecule 1
Prof. Patrick Guiry
University College Dublin
Funded Investigators:
Prof. Alan Dobson, University College Cork, Prof. Fergal O’Gara, University College Cork, Dr Marina Rubini, University College Dublin, Prof. Edmond Magner, University of Limerick, Prof. Stephen Connon, Trinity College Dublin, Dr Eoghan McGarrigle, University College Dublin, Dr Gerard McGlacken, University College Cork, Dr Paul Evans, University College Dublin, Prof. Declan Gilheany, University College Dublin, Dr Andrew Phillips, University College Dublin, Prof. Paul Murphy, NUI Galway, Dr Peter Byrne, University College Cork, Dr Stuart Collins, University College Cork, Prof. Eoin Scanlan, Trinity College Dublin, Prof. Joanna McGouran, Trinity College Dublin.

Overall Objective

To develop new methodologies for the asymmetric synthesis of existing APIs and future drug candidates with particular focus on the discovery and application of enzymes, small molecule organocatalysts and organometallic complexes for industrially-relevant, synthetic transformations.

Key Scientific Expertise

Our team consists of internationally recognised researchers with expertise in the following areas of critical interest to the pharmaceutical industry in Ireland:

Industrial Significance

N

Selecting Route

Selecting the optimal synthetic route for API Manufacture.
N

Green Pharma

Making pharma greener and continuous manufacturing.
N

Advanced Procedures

Advanced manufacturing, asymmetrically synthesising complex molecules with more chiral centres.